Richard Willke
A5037266004- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Pharmaceutical Economics and Policy
- Risk and Safety Analysis
- Healthcare cost, quality, practices
- Biomedical Ethics and Regulation
- Diabetes Treatment and Management
- Biomedical and Engineering Education
University of Maryland, College Park
2021-2023
University of York
2021-2023
Pontificia Universidad Católica de Chile
2020-2023
Abstract Under the Inflation Reduction Act's (IRA's) - Medicare Drug Price Negotiation Program, Centers for & Medicaid Services' (CMS's) “maximum fair price” must be informed by evidence on factors such as therapeutic advance of selected drug compared with its alternative, comparative effectiveness across clinical and patient-reported outcomes, impact specific populations, ability to address unmet medical needs. This paper describes how real-world could improve CMS decision-making...
Abstract This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed inventories – such as Second Panel Cost-Effectiveness’s “impact inventory” and International Society of Pharmacoeconomics Outcomes Research (ISPOR) “value flower” aimed to more comprehensively capture benefits costs new health technologies perspective. Nevertheless, application broader elements...
ABSTRACT BACKGROUND Traditional value assessment frameworks are challenged in comprehensively assessing the societal new therapies bring to individuals with rare, progressive, genetic, fatal, neuromuscular diseases such as Duchenne muscular dystrophy (DMD). OBJECTIVE To identify how may need be adapted measure society of DMD therapies. METHODS Three groups stakeholders (patient advocates, clinicians, health economists) participated semi-structured interviews around International Society for...